Zentalis Pharmaceuticals, Inc. — Cyborg Score 4/10
Mixed
Biotechnology / Oncology
Strategic Profile
The company is developing azenosertib as a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer. The Phase 2 DENALI trial remains on track with topline data expected by year-end 2026 with potential to support accelerated approval.
Cyborg Score Rationale
With a market cap of $152M and trailing 12-month revenue of $26.9M, Zentalis faces typical clinical-stage biotech risks. The company has strong cash reserves of $280.7M providing runway into late 2027, supporting program advancement, but success hinges on DENALI trial outcomes.
Top Insights
DENALI Phase 2 trial remains on track with topline data expected by year-end 2026 with potential accelerated approval pathway
Company has $280.7M in cash, providing operational runway into late 2027
TETON Phase 2 uterine serous carcinoma trial completed enrollment with results planned for H1 2026
Pipeline includes ZN-c5 (breast cancer), ZN-d5 (lymphoma/leukemia), and ZN-e4 (lung cancer) in Phase 1/2 trials
Named Competitors
ORIC Pharmaceuticals — Oncology biotech developing targeted cancer therapies
Prelude Therapeutics — Clinical-stage oncology company
Hookipa Pharma — Immunotherapy company
Recent Developments
(November 2025) Q3 2025 results: $280.7M cash runway, quarterly operating expenses $33.7M, DENALI Part 2 on track
(October 2025) Four poster presentations at AACR-NCI-EORTC conference on azenosertib clinical data and biomarker findings
(September 2025) Morgan Stanley Global Healthcare Conference presentation on development strategy
Open the full interactive Zentalis Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.